VacZine Analytics  
MarketVIEW - Chlamydia trachomatis vaccines

Updated: June 2012

Chlamydia trachomatis (CT) is an intracellular Gram-negative bacterium and a leading cause worldwide of sexually-transmitted disease and preventable blindness. The pathogen is a major cause of serious reproductive complications in the female with outcomes such as pelvic inflammatory disease (PID) and ectopic pregnancies.

Although diagnosed infections with Chlamydia trachomatis are curable with antibiotic therapy the vast majority infections are "silent" and unrecognized. This is of concern due to continued transmission especially among individuals below 30 years of age. Prophylatic vaccines could prevent CT primary infection, reinfection or lessen the incidence and severity of PID, or similar long-term sequelae. A key question for vaccine manufacturers is whether a CT vaccine would be deployed alongside HPV vaccines in the preadolescent population, thus providing a sizeable commercial opportunity.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for a putative CT vaccine until 2035. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on new adolescent vaccines.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV003 Click here>>
Discounted option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2011 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains